HER2 Support Group Forums - View Single Post

R.B. · 06-08-2007, 07:47 AM

I am not an expert and cannot offer treatment advice.

I am just bring things to you attention you may wish to discuss with your onc. DHA / EPA lipid infusions are have been been trialled with melanoma and intestinal cancers from memory showing promise. DHA /EPA infusions are from memory reported in assisting with cachexia see link below.

A trial suggested DHA might work to upgrade the effect of Taxol - Taoxotere 15 - 5 fold. I do not know if there have been trials in people as against a lab.

Just something for you to take to your onc if you are both looking for options.

RB

http://www.eurjcancerprev.com/pt/re/ejcp/abstract.00008469-200506000-00011.htm;jsessionid=GpnGN5XnCBJlShw8wDHVSZ8jqhJvs fn3thv3nxbp7QvGhB45yX2J!-1804036389!-949856145!8091!-1

Abstract

Abstract:
[omega]-3 Polyunsaturated fatty acid (PUFA), docosahexaenoic acid (DHA; 22:6n-3) and other [omega]-3 and [omega]-6 PUFAs have raised interest as novel anticancer agents by exerting selective cytotoxic effects on human cancer cells without affecting normal tissues. Here, we examined the in vitro relationship between exogenous supplementation with DHA and breast cancer chemosensitivity to taxanes. We measured cell viability in the highly metastatic human breast cancer cell line MDA-MB-231 exposed sequentially to DHA followed by paclitaxel (Taxol) or docetaxel (Taxotere). As DHA by itself showed cytotoxic effects, possible synergistic interactions between DHA and taxanes were assessed, employing the combination index (CI) method and the isobologram analysis. Both methods showed a strong synergism (CI ~0.5; P<0.005) between DHA and taxanes in MDA-MB-231 cells. When the increase in taxanes efficacy was measured by dividing the IC50 values (50% inhibitory concentrations) obtained when the cells were exposed to taxanes alone by those after DHA pre-exposure, we found that DHA enhanced the cytotoxic activity of taxanes against MDA-MB-231 cells in a dose-dependent manner (up to 13- and 5-fold increase in Taxol and Taxotere efficacy, respectively). Importantly, sequential exposure to DHA followed by taxanes also yielded strong synergism in Her-2/neu (c-erbB-2)-overexpressing and taxanes-resistant SK-Br3 and BT-474 breast cancer cells. Moreover, exogenous supplementation with DHA significantly decreased the expression of Her-2/neu-codified p185Her-2/neu oncoprotein (up to 78% reduction in BT-474 cells). Our results provide experimental support to the hypothesis that [omega]-3 PUFAs can be used as modulators of tumor cell chemosensitivity and provide the rationale for in vivo preclinical investigation. In addition, this is the first study demonstrating that [omega]-3 PUFA DHA downregulates Her-2/neu oncogene expression in human breast cancer cells.

http://www.joplink.net/prev/200603/200603_17.pdf

http://www.ncbi.nlm.nih.gov/sites/en...&dopt=Abstract

06-08-2007, 07:47 AM	#7
R.B. Senior Member Join Date: Mar 2006 Posts: 1,843	I am not an expert and cannot offer treatment advice. I am just bring things to you attention you may wish to discuss with your onc. DHA / EPA lipid infusions are have been been trialled with melanoma and intestinal cancers from memory showing promise. DHA /EPA infusions are from memory reported in assisting with cachexia see link below. A trial suggested DHA might work to upgrade the effect of Taxol - Taoxotere 15 - 5 fold. I do not know if there have been trials in people as against a lab. Just something for you to take to your onc if you are both looking for options. RB http://www.eurjcancerprev.com/pt/re/ejcp/abstract.00008469-200506000-00011.htm;jsessionid=GpnGN5XnCBJlShw8wDHVSZ8jqhJvs fn3thv3nxbp7QvGhB45yX2J!-1804036389!-949856145!8091!-1 Abstract Abstract: [omega]-3 Polyunsaturated fatty acid (PUFA), docosahexaenoic acid (DHA; 22:6n-3) and other [omega]-3 and [omega]-6 PUFAs have raised interest as novel anticancer agents by exerting selective cytotoxic effects on human cancer cells without affecting normal tissues. Here, we examined the in vitro relationship between exogenous supplementation with DHA and breast cancer chemosensitivity to taxanes. We measured cell viability in the highly metastatic human breast cancer cell line MDA-MB-231 exposed sequentially to DHA followed by paclitaxel (Taxol) or docetaxel (Taxotere). As DHA by itself showed cytotoxic effects, possible synergistic interactions between DHA and taxanes were assessed, employing the combination index (CI) method and the isobologram analysis. Both methods showed a strong synergism (CI ~0.5; P<0.005) between DHA and taxanes in MDA-MB-231 cells. When the increase in taxanes efficacy was measured by dividing the IC50 values (50% inhibitory concentrations) obtained when the cells were exposed to taxanes alone by those after DHA pre-exposure, we found that DHA enhanced the cytotoxic activity of taxanes against MDA-MB-231 cells in a dose-dependent manner (up to 13- and 5-fold increase in Taxol and Taxotere efficacy, respectively). Importantly, sequential exposure to DHA followed by taxanes also yielded strong synergism in Her-2/neu (c-erbB-2)-overexpressing and taxanes-resistant SK-Br3 and BT-474 breast cancer cells. Moreover, exogenous supplementation with DHA significantly decreased the expression of Her-2/neu-codified p185Her-2/neu oncoprotein (up to 78% reduction in BT-474 cells). Our results provide experimental support to the hypothesis that [omega]-3 PUFAs can be used as modulators of tumor cell chemosensitivity and provide the rationale for in vivo preclinical investigation. In addition, this is the first study demonstrating that [omega]-3 PUFA DHA downregulates Her-2/neu oncogene expression in human breast cancer cells. http://www.joplink.net/prev/200603/200603_17.pdf http://www.ncbi.nlm.nih.gov/sites/en...&dopt=Abstract